Abstract:Triterpenoids are crucial active ingredients of Ganoderma lucidum (G. lucidum) with various health benefits. Yet the low biosynthesis greatly restricts their industrial applications, novel metabolic engineering strategies are needed to further enhance Ganoderma triterpenoids production. Transcription factors play vital roles in the metabolic regulation of terpenoids, which are still scarce to study in G. lucidum. Herein, a transcription factor GlbHLH5 (GenBank No. ) potential for metabolic regulation of Ganoderma triterpenes was identified for the first time. MeJA could increase Ganoderma triterpenoids biosynthesis, and GlbHLH5 significantly responded to MeJA induction, suggesting GlbHLH5 is a new target for Ganoderma triterpenoids overproduction. The regulatory effect of the newly identified target was further validated by homologous gene overexpression and silence in G. lucidum. It's demonstrated that overexpression of GlbHLH5 significantly increased triterpenoids accumulation and the key enzyme genes transcription in the biosynthetic pathway, while silencing it displayed the opposite effect, indicating GlbHLH5 could positively regulate the triterpenoids biosynthesis by activating the synergistic expression of key enzyme genes in the biosynthetic pathway. Consequently, GlbHLH5 was identified as a positive regulator and novel metabolic target for Ganoderma triterpenoids biosynthesis, it sheds new lights on the regulatory effect regulation and synthetic biology of Ganoderma triterpenoids.

Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMGs reductase, aldose reductase and α-glucosidase

Identification of a Novel Metabolic Target for Bioactive Triterpenoids Biosynthesis in <i>Ganoderma</i> lucidum

Anti-human immunodeficiency virus-1 protease activity of new lanostane-type triterpenoids from Ganoderma sinense.

Triterpenoids and meroterpenoids with α-glucosidase inhibitory activities from the fruiting bodies of Ganoderma australe

New ganoderic acids, bioactive triterpenoid metabolites from the mushroom Ganoderma lucidum

Antidiabetic lanostane triterpenoids from the fruiting bodies of Ganoderma weberianum

Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase

Lanostane triterpenoids with anti-proliferative and PTP1B/α-glucosidase inhibitory activities from the fruiting bodies of Ganoderma calidophilum

[Triterpenoids from Ganoderma theaecolum]

Lanostane triterpenoids from Ganoderma lucidum and their inhibitory effects against FAAH

Triterpenoids with neurotrophic activity from Ganoderma lucidum.

Triterpenoids from the fruiting bodies of Ganoderma lucidum and their inhibitory activity against FAAH

Cytotoxic lanostanoid triterpenes from Ganoderma lucidum.

Ganospirones A-G, seven undescribed spiro-meroterpenoids from Ganoderma lucidum and their biological activities

Lanostane triterpenoids from the fruiting bodies of Ganoderma amboinense

New Lanostane-Type Triterpenoids from the Fruiting Body of Ganoderma Hainanense

Cytotoxic Triterpenoids from Ganoderma Lucidum

Lanostane triterpenoids with anti-proliferative and anti-inflammatory activities from medicinal mushroom Ganoderma lingzhi

Triterpenes from antler-shaped fruiting body of Ganoderma lucidum and their hepatoprotective activities

Nor-triterpenoids from the fruiting bodies of Ganoderma lucidum and their inhibitory activity against FAAH

Methyl Lucidenate F Isolated from the Ethanol-Soluble-acidic Components of Ganoderma Lucidum is a Novel Tyrosinase Inhibitor